NCT01120912

Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients

A Single Center, Non-randomized, Single Blind, Placebo Controlled, Single Dose Study of the Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients - Phase 1 Study

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Oshadi Drug Administration · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study will be a non-randomized, open label, single dose, single blind, placebo control, single center, single arm study in Type I diabetes patients. The study will include single dose administration for the evaluation of single dose acute toxicity, pharmacokinetics and activity.

Conditions

• Diabetes

Interventions

Type	Name	Description
DRUG	Oshadi Oral Insulin	Oral insulin single administration

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-02-01
• Completion: 2011-02-01
• First posted: 2010-05-11
• Last updated: 2012-04-17

Locations

1 site across 1 country: Israel